Enhancement of anti-inflammatory property of aspirin in mice by a nano-emulsion preparation

Subramanian, Balajikarthick; Kuo, Fonghsu; Ada, Earl T.; Kotyla, Tim; Wilson, Thomas A.; Yoganathan, Subbiah; Nicolosi, Robert J.

doi:10.1016/j.intimp.2008.06.009

Cited by 47 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our laboratory has successfully formulated nutrients such as delta-tocopherol [14] and gammatocopherol [15] into stable nanoemulsion water dispersions and demonstrated increased bioavailability compared to microemulsions using animal models. In addition, other labs using nano-preparations of paclitaxel [16], as well as our reported studies have shown increased bioavailability and efficacy of nanoformulations of anti-cancer drugs such as tamoxifen [17] and dacarbazine [18] and anti-inflammatory compounds such as aspirin [19] compared to micro-suspensions using cell culture and animal models.…”

Section: Introductionmentioning

confidence: 59%

“…Nanoemulsion delivery systems have previously been shown to improve bioavailability of nutrients such as delta-tocopherol, calcium and the vitamin-like coenzyme Q-10 molecule [14,27,28]. Pre-clinical studies have shown increased anti-cancer activity of drugs such as tamoxifen and dacarbazine, enhanced antiinflammatory property of aspirin, improved bioactivity of insulin when delivered as nanoemulsions [17][18][19]29]. Paclitaxel nanoformulation showed increased bioavailability, efficacy and reduced toxicity in a clinical study [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Vishwanathan¹,

Wilson²,

Nicolosi³

2009

Nano BioMed ENG

View full text Add to dashboard Cite

Lutein, a lipid soluble, oxygenated carotenoid, has shown beneficial effects against the risk factors associated with age-related macular degeneration, cardiovascular disease and also damaging UV radiation. The goal of the present study was to formulate lutein into a stable hydrophilic nanoemulsion that is more bioavailable and consumable in a matrix such as a beverage rather than just supplements. A Microfluidizer® Processor was used to convert an oil-in-water lutein emulsion into a nanoemulsion that is a stable water dispersion and measures 150 nm. After a one wk baseline phase, subjects consumed a lutein supplement pill followed by a lutein nanoemulsion added to orange juice (6 mg/d and 2 mg/d in two separate studies) for one wk each with a 2 wk washout phase between treatments. In study 1, mean serum lutein concentrations (n = 9) increased by 104% (P < 0.001) and 167% (P < 0.001) after the 6 mg supplement and nanoemulsion phases, respectively. In study 2, mean serum lutein concentrations (n = 11) increased by 37% (P < 0.05) and 75% (P < 0.001) after the 2 mg lutein supplement and nanoemulsion phases, respectively Despite the fact that the actual concentration of lutein in the 6 mg and 2 mg nanoemulsions was 10% and 40% lower compared to the supplement form, respectively, due to Microfluidizer ® processor preparation loss, the nanoemulsions resulted in 31% (P < 0.05) and 28% (P < 0.05) greater serum lutein concentrations compared to the supplement.. In conclusion, nanoemulsions of lutein had significantly greater bioavailability than the supplement-pill forms. Keywords:

show abstract

Section: Introductionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Vishwanathan¹,

Wilson²,

Nicolosi³

2009

Nano BioMed ENG

View full text Add to dashboard Cite

show abstract

“…is very important since these drugs are able to act immediately because they do not need to cross extra barriers. The drug is bioavailable easily and faster [204][205][206][207][208][209][210].…”

Section: Applications Of Nanocarrier Systems In Topical/transdermal Dmentioning

confidence: 99%

Nanocarrier Systems for Transdermal Drug Delivery

Escobar-Chávez¹,

Rodríguez-Cruz²,

Domínguez-Delgado³

et al. 2012

Recent Advances in Novel Drug Carrier Systems

View full text Add to dashboard Cite

is an open discussion, in one hand, the nanotechnologist continue making new and more sophisticated nanocarriers and in the other hand, toxicologist continue evaluating possible damaging effects.Whatever it happens, nanotechnology is the new era and nanomedicine cannot be taking off. New nanocarriers will be created and the entire scientist working in nanomedicine bet for it to be the cure of diseases that in this moment are difficult to deal with [3] The application of preparations to the skin for medical purposes is as old as the history of medicine itself, with references to the use of ointments and salves found in the records of Babylonian and Egyptian medicine. The historical development of permeation research is well described by Hadgraft & Lane [4]. Over time, the skin has become an important route for drug delivery in which topical, regional or systemic effects are desired. Nevertheless, skin constitutes an excellent barrier and presents difficulties for the transdermal delivery of therapeutic agents, since few drugs possess the characteristics required to permeate across the stratum corneum in sufficient quantities to reach a therapeutic concentration in the blood. In order to enhance drug transdermal absorption different methodologies have been investigated developed and patented [5,6]. Improvement in physical permeationenhancement technologies has led to renewed interest in transdermal drug delivery. Some of these novel advanced transdermal permeation enhancement technologies include: iontophoresis, electroporation, ultrasound, microneedles to open up the skin and more recently the use of transdermal nanocarriers [3,[7][8][9][10].A number of excellent reviews that have been published contain detailed discussions concerning many aspects of transdermal nanocarriers [11][12][13][14][15][16][17]. The present chapter shows an updated overview of the use of submicron particles and other nanostructures in the pharmaceutical field, specifically in the area of topical and transdermal drugs. This focus is justified due to the magnitude of the experimental data available with the use of these nanocarriers. The development of submicron particles and other nanostructures in the pharmaceutical and cosmetic fields has been emerged in the last decades for designing best formulations for application through the skin [18][19][20][21]. The skinThe skin is the largest organ of the body [22][23][24], accounting for more than 10% of body mass, and the one that enables the body to interact more intimately with its environment. Essentially, the skin consists of four layers: The SC, that is the outer layer of the skin (nonviable epidermis), and forms the rate-controlling barrier for diffusion for almost all compounds. It is composed of dead flattened, keratin-rich cells, the corneocytes. These dense cells are surrounded by a complex mixture of intercellular lipids, namely, ceramides, free fatty acids, cholesterol, and cholesterol sulphate. Their most important feature is that they are structured as ordered bilayer arrays [25]...

show abstract

“…The nanoemulsions are often referred to as "Approaching Thermodynamic Stability" [25]. Compared to typical suspension preparations which can be thousands of nanometers in size, nanoemulsion delivery systems utilized and reported from our lab [28][29][30][31][32] as well as those of others with particle sizes approximately 100 nm or less have been shown to increase bioavailability and efficacy of a number of compounds [25,33,34]. The concept of zeta potential and how its reduction can be associated with increased efficacy of drug delivery systems has been raised by reports from our lab [30,33] and others [35][36][37].…”

Section: Articlementioning

confidence: 99%

In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines

Bagul¹,

Kakumanu²,

Wilson³

et al. 2010

Nano BioMed ENG

Self Cite

View full text Add to dashboard Cite

Paclitaxel is routinely used in cancer chemotherapy to treat patients with ovarian, breast, lung, head and neck cancers. However, because of its low aqueous solubility, it's been administered as a Cremophor EL and ethanol solution, which is associated with increased toxicity and high therapeutic dose requirements. The goal of the present study was to formulate paclitaxel into a self assembling nanoemulsion (SANE) and demonstrate the effects of paclitaxel SANE formulation on the inhibition of cell proliferation in breast (80 %), colon (60 %), and pancreatic cell lines (60 %) compared to blank nanoemulsion. In addition, nanoemulsions of paclitaxel with a mean particle size of 20 nm dramatically reduced zeta potential and showed up to 12 fold greater apoptosis in the PL-45 pancreatic cancer cell line compared to a blank nanoemulsion. In conclusion we have developed a SANE formulation of paclitaxel having a particle size of 20 nm which significantly inhibited cell proliferation, dramatically reduced zeta potential and increased apoptosis by 12-fold when compared to a blank and nanoemulsion, thus indicating the therapeutic potential for SANE as an anti-cancer drug delivery system.

show abstract

Enhancement of anti-inflammatory property of aspirin in mice by a nano-emulsion preparation

Cited by 47 publications

References 40 publications

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Nanocarrier Systems for Transdermal Drug Delivery

In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines

Contact Info

Product

Resources

About